Mary Wilson
Well-known member
Published 24 March 2023
DOI https://doi.org/10.1038/s41541-023-00643-9
Cindy Hörner, Anna H. Fiedler, Bianca S. Bodmer, Lisa Walz, Vivian A. Scheuplein, Stefan Hutzler,
Mikhail N. Matrosovich, Veronika von Messling & Michael D. Mühlebach
Abstract
A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines. To characterize the efficacy of H7N9 antigens in a prototypic vaccine platform technology, we generated MeVs encoding either neuraminidase (N9) or hemagglutinin (H7). Moraten vaccine strain-derived vaccine candidates were rescued; they replicated with efficiency comparable to that of the measles vaccine, robustly expressed H7 and N9, and were genetically stable over 10 passages. Immunization of MeV-susceptible mice triggered the production of antibodies against H7 and N9, including hemagglutination-inhibiting and neutralizing antibodies induced by MV[SUB]vac2[/SUB]-H7(P) and neuraminidase-inhibiting antibodies by MV[SUB]vac2[/SUB]-N9(P). Vaccinated mice also developed long-lasting H7- and N9-specific T cells. Both MV[SUB]vac2[/SUB]-H7(P) and MV[SUB]vac2[/SUB]-N9(P)-vaccinated mice were protected from lethal H7N9 challenge.
https://www.nature.com/articles/s41541-023-00643-9#citeas
DOI https://doi.org/10.1038/s41541-023-00643-9
Cindy Hörner, Anna H. Fiedler, Bianca S. Bodmer, Lisa Walz, Vivian A. Scheuplein, Stefan Hutzler,
Mikhail N. Matrosovich, Veronika von Messling & Michael D. Mühlebach
Abstract
A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines. To characterize the efficacy of H7N9 antigens in a prototypic vaccine platform technology, we generated MeVs encoding either neuraminidase (N9) or hemagglutinin (H7). Moraten vaccine strain-derived vaccine candidates were rescued; they replicated with efficiency comparable to that of the measles vaccine, robustly expressed H7 and N9, and were genetically stable over 10 passages. Immunization of MeV-susceptible mice triggered the production of antibodies against H7 and N9, including hemagglutination-inhibiting and neutralizing antibodies induced by MV[SUB]vac2[/SUB]-H7(P) and neuraminidase-inhibiting antibodies by MV[SUB]vac2[/SUB]-N9(P). Vaccinated mice also developed long-lasting H7- and N9-specific T cells. Both MV[SUB]vac2[/SUB]-H7(P) and MV[SUB]vac2[/SUB]-N9(P)-vaccinated mice were protected from lethal H7N9 challenge.
https://www.nature.com/articles/s41541-023-00643-9#citeas